Story perspectives

Tamoxifen Linked to Uterine Cancer Risk, Study Reveals

8/23/2025

48 7

Summary

Story summary

A study indicates tamoxifen may stimulate uterine cell growth, raising the risk of secondary uterine cancers in breast cancer patients.
Researchers discovered tamoxifen activates the PI3K-AKT signaling pathway without inducing genetic mutations.
Treatment with the PI3K inhibitor alpelisib decreased uterine cell proliferation in mice, offering a potential strategy to reduce tamoxifen's side effects.
The study calls for clinical trials to evaluate the safety of combining tamoxifen with PI3K inhibitors.

1 of 1

Story summary

A study indicates tamoxifen may stimulate uterine cell growth, raising the risk of secondary uterine cancers in breast cancer patients.
Researchers discovered tamoxifen activates the PI3K-AKT signaling pathway without inducing genetic mutations.
Treatment with the PI3K inhibitor alpelisib decreased uterine cell proliferation in mice, offering a potential strategy to reduce tamoxifen's side effects.
The study calls for clinical trials to evaluate the safety of combining tamoxifen with PI3K inhibitors.